Shares of Provenge maker Dendreon Corp. (Nasdaq: DNDN) tumbled 93 cents to $9.95 after Johnson & Johnson (NYSE: JNJ) reported positive results from a late stage clinical trial of its prostate cancer treatment Zytiga. Johnson & Johnson stock gained 66 cents to $64.96.
Dendreon Drops On Johnson & Johnson's Upbeat Trial Results
March 08, 2012 at 12:31 PM EST
